Day: November 2, 2025
MHRA response is based on the Phase 3 DRAGON interim analysis results
Topline final data expected in Q4 2025SAN DIEGO, Nov. 02, 2025 (GLOBE NEWSWIRE) — Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has agreed to accept a Conditional Marketing Authorization application for Tinlarebant for the treatment of Stargardt disease based on the interim analysis results from the Phase 3 DRAGON trial.
“We are extremely pleased with the outcome of our engagement with the MHRA. This is an incredibly exciting time for the Belite team as we see our perseverance bringing us closer to offering an...
Fangzhou’s “XingJie” LLM Completes Key National Filing, Setting Stage for Further AI-Driven Chronic Care Innovations
Written by Customer Service on . Posted in Public Companies.
SHENZHEN, China, Nov. 02, 2025 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leader in AI-driven Internet healthcare solutions, was presented with a Generative AI Service Filing Certificate at the first Guangdong Provincial LLM Filing Conference in Shenzhen.
At the event, Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou, remarked: “The successful launch of the ‘XingJie’ Large Language Model (‘XJ LLM’) marks another milestone in Fangzhou’s advancement of AI-driven chronic disease management. Building on this momentum, we will continue to optimize our models and enrich our AI+H2H (Hospital-to-Home) healthcare ecosystem, integrating frontier AI capabilities with professional medical services so that every user can experience smarter, more accessible, and more personalized care support.”
Dr....
